Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2025 07:03 ET | Source: Sagimet Biosciences Inc.

Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
December 09, 2025 16:05 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
November 20, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
November 13, 2025 07:30 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567...
November 10, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI)...
October 24, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis...
October 14, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
October 07, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
October 01, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are...
September 24, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...